Cited by 78Fatty Acid Research and HealthLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice

Open access
Tanaka, Naoki, Zhang, Xiuguo, Sugiyama, Eiko, Kono, Hiroyuki, Horiuchi, Akira, Nakajima, Takero, Kanbe, Hiroki, Tanaka, Eiji +2 more·2010·Biochemical Pharmacology

Abstract

Eicosapentaenoic acid (EPA) in fish oil is known to improve hepatic steatosis. However, it remains unclear whether such action of EPA is actually caused by peroxisome proliferator-activated receptor α (PPARα) activation. To explore the contribution of PPARα to the effects of EPA itself, male wild-type and Ppara-null mice were fed a saturated fat diet for 16 weeks, and highly (>98%)-purified EPA was administered in the last 12 weeks. Furthermore, the changes caused by EPA treatment were compared to those elicited by fenofibrate (FF), a typical PPARα activator. A saturated fat diet caused macrovesicular steatosis in both genotypes. However, EPA ameliorated steatosis only in wild-type mice without PPARα activation, which was evidently different from numerous previous observations. Instead, EPA inhibited maturation of sterol-responsive element-binding protein (SREBP)-1 in the presence of PPARα through down-regulation of SREBP cleavage-activating protein and site-1 protease. Additionally, EPA suppressed fatty acid uptake and promoted hydrolysis of intrahepatic triglycerides in a PPARα-independent manner. These effects were distinct from those of fenofibrate. Although fenofibrate induced NAPDH oxidase and acyl-coenzyme A oxidase and significantly increased hepatic lipid peroxides, EPA caused PPARα-dependent induction of superoxide dismutases, probably contributing to a decrease in the lipid peroxides. These results firstly demonstrate detailed mechanisms of steatosis-ameliorating effects of EPA without PPARα activation and ensuing augmentation of hepatic oxidative stress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2010.07.031

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 49 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Tanaka, N., Zhang, X., Sugiyama, E., Kono, H., Horiuchi, A., Nakajima, T., Kanbe, H., Tanaka, E., Gonzalez, F. J., & Aoyama, T.
Affiliations
  • Shinshu University (JP)
  • Nagano Prefectural College (JP)
  • Mochida Pharmaceutical (Japan) (JP)
  • Showa Inan General Hospital (JP)
  • National Institutes of Health (US)
Corresponding author
  • Tanaka, Naoki
  • Sugiyama, Eiko
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2010-11
Volume
80
Issue
10
Pages
1601-1612
ISSN
0006-2952 (ISSN-L)
OpenAlex
W2050883328
Cited by
78
References
49
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 14
FWCI
9.71
Type
journal article
Language
en
Open access
Locations
  • Biochemical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (Z01BC005561)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
eicosapentaenoic acid, hepatic steatosis, PPARα, SCAP, site-1 protease, fatty acid uptake, lipolysis, fenofibrate, dietary saturated fat, oxidative stress, lipid peroxidation, superoxide dismutase, fish oil
MeSH terms
Animals, Dietary Fats, Disease Models, Animal, Fatty Liver, Genotype, Liver, Liver Function Tests, Male, Fenofibrate, Eicosapentaenoic Acid, Immunoblotting, Lipid Peroxidation, Mice, Knockout, Oxidative Stress, PPAR alpha, Mice, Sterol Regulatory Element Binding Protein 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review